$MRUS
Merus N.V.

2022 Q3 Form 10-Q Financial Statement

#000095017022015517 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $6.581M $12.68M $11.66M
YoY Change -51.85% 2.46% 39.58%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.47M $12.70M $11.75M
YoY Change 22.59% 20.12% 25.97%
% of Gross Profit
Research & Development $42.31M $31.10M $26.98M
YoY Change 62.61% 26.34% 29.65%
% of Gross Profit
Depreciation & Amortization $300.0K $322.0K $351.0K
YoY Change -21.87% -17.65% 8.33%
% of Gross Profit
Operating Expenses $54.78M $43.79M $38.73M
YoY Change 51.36% 24.47% 28.5%
Operating Profit -$48.20M -$31.11M -$27.07M
YoY Change 114.01% 36.42% 24.25%
Interest Expense $23.91M $24.92M $7.836M
YoY Change 209.24% -644.65% -35.35%
% of Operating Profit
Other Income/Expense, Net $23.91M $25.52M $8.294M
YoY Change -31976.0% -664.19% -29.01%
Pretax Income -$24.29M -$5.583M -$18.78M
YoY Change 63.4% -79.57% 85.84%
Income Tax $327.0K $131.0K $114.0K
% Of Pretax Income
Net Earnings -$24.62M -$5.714M -$18.89M
YoY Change 65.72% -79.14% 86.06%
Net Earnings / Revenue -374.03% -45.05% -162.1%
Basic Earnings Per Share -$0.53 -$0.13 -$0.43
Diluted Earnings Per Share -$0.53 -$0.13 -$434.4K
COMMON SHARES
Basic Shares Outstanding 45.88M 43.64M 43.49B
Diluted Shares Outstanding 46.06M 43.64M 43.49B

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $351.4M $376.1M $358.8M
YoY Change 13.46% 6.62% -4.16%
Cash & Equivalents $191.0M $213.9M $194.6M
Short-Term Investments $160.5M $162.2M $164.2M
Other Short-Term Assets $951.0K $2.617M $2.434M
YoY Change -16.51% 91.3% 78.18%
Inventory
Prepaid Expenses
Receivables $2.628M $3.896M $2.671M
Other Receivables $519.0K $476.0K $496.0K
Total Short-Term Assets $368.2M $398.8M $379.7M
YoY Change 15.16% 8.67% -1.66%
LONG-TERM ASSETS
Property, Plant & Equipment $7.339M $6.179M $6.843M
YoY Change -3.35% -26.07% 81.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $21.48M $20.69M $25.47M
YoY Change -8.57%
Other Assets $3.307M $3.189M $3.225M
YoY Change 24.7% 96.49% 72.28%
Total Long-Term Assets $46.79M $45.97M $37.77M
YoY Change 29.24% 265.14% 219.38%
TOTAL ASSETS
Total Short-Term Assets $368.2M $398.8M $379.7M
Total Long-Term Assets $46.79M $45.97M $37.77M
Total Assets $415.0M $444.8M $417.5M
YoY Change 16.59% 17.18% 4.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.117M $6.961M $5.388M
YoY Change -42.29% 13.0% 45.03%
Accrued Expenses $33.06M $22.59M $22.44M
YoY Change 13.87% -13.54% -4.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $64.15M $60.26M $61.52M
YoY Change -10.32% -6.43% 16.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $52.06M $57.92M $58.50M
YoY Change -33.78% -39.72% -46.08%
Total Long-Term Liabilities $52.06M $57.92M $58.50M
YoY Change -33.78% -39.72% -46.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.15M $60.26M $61.52M
Total Long-Term Liabilities $52.06M $57.92M $58.50M
Total Liabilities $116.2M $118.2M $120.0M
YoY Change -22.61% -26.36% -25.64%
SHAREHOLDERS EQUITY
Retained Earnings -$516.2M -$491.5M -$485.8M
YoY Change 14.08% 12.29% 18.4%
Common Stock $869.6M $853.3M $798.6M
YoY Change 30.56% 23.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $298.8M $326.6M $297.5M
YoY Change
Total Liabilities & Shareholders Equity $415.0M $444.8M $417.5M
YoY Change 16.59% 17.18% 4.91%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$24.62M -$5.714M -$18.89M
YoY Change 65.72% -79.14% 86.06%
Depreciation, Depletion And Amortization $300.0K $322.0K $351.0K
YoY Change -21.87% -17.65% 8.33%
Cash From Operating Activities -$41.26M -$31.73M -$46.40M
YoY Change 78.79% 30.62% -339.86%
INVESTING ACTIVITIES
Capital Expenditures -$2.331M -$2.858M $342.0K
YoY Change 741.52% 2758.0% 117.83%
Acquisitions
YoY Change
Other Investing Activities $1.190M $6.912M -$625.0K
YoY Change -100.89% 18.5% -75.2%
Cash From Investing Activities -$1.141M $4.054M -$967.0K
YoY Change -99.15% -29.16% -63.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.876M 48.20M 879.0K
YoY Change 280.58% 2494.13% -99.42%
NET CHANGE
Cash From Operating Activities -41.26M -31.73M -46.40M
Cash From Investing Activities -1.141M 4.054M -967.0K
Cash From Financing Activities 9.876M 48.20M 879.0K
Net Change In Cash -32.52M 20.52M -47.36M
YoY Change -78.94% -222.77% -128.87%
FREE CASH FLOW
Cash From Operating Activities -$41.26M -$31.73M -$46.40M
Capital Expenditures -$2.331M -$2.858M $342.0K
Free Cash Flow -$38.93M -$28.88M -$46.74M
YoY Change 70.74% 19.35% -343.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-466928000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
326609000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
316201000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
444793000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
456600000
CY2022Q2 us-gaap Revenues
Revenues
12684000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4481000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
848623000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
787869000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-35190000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9221000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-491535000
CY2021Q2 us-gaap Revenues
Revenues
12379000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
18048000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
60263000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71898000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12291000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2257000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
45630000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10962000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43467052
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
2347000
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
241000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
417000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3189000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2078000
CY2022Q2 us-gaap Assets
Assets
444793000
CY2021Q4 us-gaap Assets
Assets
456600000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6961000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13237000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21257000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
22506000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1331000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1494000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
30714000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16613000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001651311
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37773
dei Entity Registrant Name
EntityRegistrantName
MERUS N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
dei Entity Address Address Line1
EntityAddressAddressLine1
Yalelaan 62
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
3584 CM
dei Entity Address City Or Town
EntityAddressCityOrTown
Utrecht
dei Entity Address Country
EntityAddressCountry
NL
dei City Area Code
CityAreaCode
+31 85
dei Local Phone Number
LocalPhoneNumber
016 2500
dei Security12b Title
Security12bTitle
Common shares, nominal value €0.09 per share
dei Trading Symbol
TradingSymbol
MRUS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45878167
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
213930000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
241435000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
162177000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
168990000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3896000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1697000
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
4609000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18822000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7448000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
398825000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
424179000
CY2022Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
20694000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
20297000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6179000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3549000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13589000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3733000
CY2022Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
2076000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43467052
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
4711000
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
55282000
CY2022Q2 us-gaap Liabilities
Liabilities
118184000
CY2021Q4 us-gaap Liabilities
Liabilities
140399000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.09
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.09
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
67500000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
67500000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45866820
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45866820
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5916000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19921000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3200000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
260000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3053000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
120006000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24850000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3475000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-25969000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5714000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10569000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24448000
us-gaap Revenues
Revenues
24339000
us-gaap Revenues
Revenues
20729000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31096000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24612000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58071000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45418000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12695000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19902000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
43791000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
35181000
us-gaap Operating Expenses
OperatingExpenses
82519000
us-gaap Operating Expenses
OperatingExpenses
65320000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-31107000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22802000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58180000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44591000
CY2022Q2 mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
316000
CY2021Q2 mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
-51000
mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
422000
mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
-133000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
24607000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4525000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
32337000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7678000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
601000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1059000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-385000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25524000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4524000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33818000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7160000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5583000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27326000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24362000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37431000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
62000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
245000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
111000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5714000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-27388000
us-gaap Net Income Loss
NetIncomeLoss
-24607000
us-gaap Net Income Loss
NetIncomeLoss
-37542000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19921000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
326609000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25635000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-23913000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-50576000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-43458000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43636000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43636000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38376000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38376000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43781000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43781000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37299000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37299000
us-gaap Profit Loss
ProfitLoss
-24607000
us-gaap Profit Loss
ProfitLoss
-37542000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
538000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
634000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
135000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
147000
mrus Foreign Exchange Gain
ForeignExchangeGain
50072000
mrus Foreign Exchange Gain
ForeignExchangeGain
7611000
us-gaap Share Based Compensation
ShareBasedCompensation
11996000
us-gaap Share Based Compensation
ShareBasedCompensation
7959000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
504000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
48000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
176000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
270000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2014000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2097000
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-18000
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
11000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4014000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1852000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6068000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3190000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
486000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3207000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17265000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
28704000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78131000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4954000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3087000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
126293000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
28163000
CY2022Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
195244000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
194971000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18893000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
297473000
CY2021Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
47000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
19000
CY2022Q2 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
184000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48015000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129398000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1063000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6728000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
285000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49078000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
152318000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1176000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2027000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27142000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
148390000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
241749000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163283000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214607000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311673000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11493000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1662000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
491000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
616000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000
mrus Non Cash Issuance Of Stock Options
NonCashIssuanceOfStockOptions
0
mrus Non Cash Issuance Of Stock Options
NonCashIssuanceOfStockOptions
573000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
213930000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311472000
CY2022Q2 mrus Restricted Cash And Non Current Other Assets
RestrictedCashAndNonCurrentOtherAssets
677000
CY2021Q2 mrus Restricted Cash And Non Current Other Assets
RestrictedCashAndNonCurrentOtherAssets
201000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
214607000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311673000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
102263000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
129403000
CY2021Q1 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
4824000
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
285000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3400000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9391000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10154000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
236537000
CY2021Q2 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
1904000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4559000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3475000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-27388000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
219087000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
316201000
CY2022Q1 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
879000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5334000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6048000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6662000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-47000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Merus N.V. is a clinical-stage oncology company developing innovative antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the “Company”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has generated an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">491.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2022. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved antibody candidate.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations, business development and licensing opportunities with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company’s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on the Company’s current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">396.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, will fund the Company’s operations beyond 2024.</span></p>
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-491500000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
396800000
CY2022Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
195244000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
194971000
CY2022Q2 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
194144000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
194773000
CY2022Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
292000
CY2022Q2 mrus Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
10840000
CY2021Q4 mrus Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2146000
CY2022Q2 mrus Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
4889000
CY2021Q4 mrus Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
2760000
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
476000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
367000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2617000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2175000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18822000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7448000
CY2022Q2 mrus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
15484000
CY2021Q4 mrus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
15174000
CY2022Q2 mrus Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
2754000
CY2021Q4 mrus Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
4861000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2974000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1362000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
45000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1109000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21257000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
22506000
CY2022Q2 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
221000
CY2021Q2 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
114000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
50000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-112000
CY2022Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
71000
CY2022Q2 mrus Additional Development Or Commercialization Milestones Achieved
AdditionalDevelopmentOrCommercializationMilestonesAchieved
0
mrus Additional Development Or Commercialization Milestones Achieved
AdditionalDevelopmentOrCommercializationMilestonesAchieved
0
CY2021Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
161000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
69000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-159000
CY2022Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-114000
CY2021Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-54000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
124000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
207000
CY2022Q2 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-47000
CY2021Q2 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-45000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
52000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
63000
CY2022Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-161000
CY2021Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-99000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
176000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
270000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
62000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
245000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
111000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
730000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
434000
us-gaap Operating Lease Cost
OperatingLeaseCost
1115000
us-gaap Operating Lease Cost
OperatingLeaseCost
852000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
123000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
132000
us-gaap Variable Lease Cost
VariableLeaseCost
199000
us-gaap Variable Lease Cost
VariableLeaseCost
223000
CY2022Q2 us-gaap Lease Cost
LeaseCost
853000
CY2021Q2 us-gaap Lease Cost
LeaseCost
566000
us-gaap Lease Cost
LeaseCost
1314000
us-gaap Lease Cost
LeaseCost
1075000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
749000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
428000
us-gaap Operating Lease Payments
OperatingLeasePayments
1148000
us-gaap Operating Lease Payments
OperatingLeasePayments
863000
CY2022Q2 mrus Development Milestones Achieved
DevelopmentMilestonesAchieved
1000000.0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6662000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4559000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11996000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7959000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Black Scholes option pricing model
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1772878
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.763
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M18D
CY2020 us-gaap Severance Costs1
SeveranceCosts1
100000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
200000
CY2022Q2 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
0
CY2022Q2 us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
0

Files In Submission

Name View Source Status
0000950170-22-015517-index-headers.html Edgar Link pending
0000950170-22-015517-index.html Edgar Link pending
0000950170-22-015517.txt Edgar Link pending
0000950170-22-015517-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrus-20220630.htm Edgar Link pending
mrus-20220630.xsd Edgar Link pending
mrus-ex31_1.htm Edgar Link pending
mrus-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mrus-20220630_lab.xml Edgar Link unprocessable
mrus-20220630_pre.xml Edgar Link unprocessable
mrus-20220630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
mrus-20220630_cal.xml Edgar Link unprocessable
mrus-20220630_def.xml Edgar Link unprocessable